Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on Talquetamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects the blood. The study is testing a new treatment called Talquetamab, also known by its code name JNJ-64407564. Talquetamab is a special type of medicine known as a bispecific antibody, which is designed to help the body's immune system target and fight cancer cells more effectively. The trial also involves another medication called Tocilizumab, which is used to help manage certain side effects that might occur during the treatment.

The purpose of this study is to understand how safe Talquetamab is for patients and to determine the best dose to use in future studies. The trial will also look at how well Talquetamab works in treating Multiple Myeloma. Participants in the study will receive Talquetamab through injections under the skin or through an infusion into a vein. Some participants will also receive Tocilizumab to help prevent or reduce side effects. The study will be conducted in different phases, starting with a small group of participants to find the right dose, and then expanding to include more participants to further evaluate the treatment's effectiveness and safety.

Throughout the study, participants will be closely monitored by healthcare professionals to track any side effects and to see how well the treatment is working against Multiple Myeloma. The study aims to provide valuable information that could lead to new treatment options for people with this type of cancer. Participants will be required to visit the study site regularly for treatment and check-ups, and the study is expected to continue for several years to gather comprehensive data.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and current health status.

    Eligibility criteria include being 18 years or older, having a documented diagnosis of multiple myeloma, and having previously received at least three lines of therapy.

  2. Step 2

    Treatment phase 1

    The first phase of treatment involves the administration of talquetamab through subcutaneous injection. The dosage and frequency are determined based on individual health assessments.

    During this phase, the safety of talquetamab is closely monitored to determine the appropriate dose for the next phase.

  3. Step 3

    Treatment phase 2

    In the second phase, the recommended dose of talquetamab is administered. This phase aims to further evaluate the safety and effectiveness of the treatment.

    Regular monitoring continues to assess any side effects or adverse reactions.

  4. Step 4

    Tocilizumab administration

    To manage potential side effects, tocilizumab is administered intravenously. This medication helps prevent or reduce inflammation-related reactions.

    The frequency and dosage of tocilizumab are adjusted based on individual response and tolerance.

  5. Step 5

    Ongoing monitoring

    Throughout the trial, regular health assessments are conducted to monitor the patient's response to the treatment.

    These assessments include blood tests, imaging studies, and other evaluations as necessary to ensure safety and effectiveness.

  6. Step 6

    Completion and follow-up

    Upon completion of the treatment phases, a final assessment is conducted to evaluate the overall response to the therapy.

    Follow-up visits may be scheduled to monitor long-term effects and gather additional data on the treatment's impact.

Who can join the trial?

11 criteria

  • Must be **18 years of age** or older.
  • Must have a **documented initial diagnosis** of multiple myeloma, which is a type of blood cancer.
  • For Part 1: Must have multiple myeloma that can be measured and has worsened after trying all available treatments, or could not tolerate them.
  • For Part 2: Must have multiple myeloma that can be measured by a central lab and has worsened after trying all available treatments, or could not tolerate them. This includes specific levels of certain proteins in the blood or urine.
  • For Part 3: Must have measurable disease for Cohorts A, B, and C, with specific protein levels in the blood or urine.
  • For Cohort A and C: Must have tried at least three different treatments, including a **proteasome inhibitor (PI)**, an **immunomodulatory drug (IMiD)**, and an **anti-CD38 monoclonal antibody**, but not treatments like **CAR-T** or **bispecific antibodies**.
  • For Cohort B: Must have tried at least three different treatments, including a PI, an IMiD, and an anti-CD38 monoclonal antibody, and have been treated with CAR-T or bispecific antibodies.
  • Must have completed at least one full cycle of treatment for each therapy tried, unless the disease worsened during that treatment.
  • Must have evidence of the disease getting worse based on specific criteria within 12 months of the last treatment, except for those who had CAR-T as their last treatment.
  • Must have an **ECOG performance status** score of 0 or 1 for Parts 1 and 2, and 0-2 for Part 3. This score measures how well a person can perform daily activities.
  • Must have certain clinical lab values that meet specific criteria during the screening phase before starting the trial.

Who cannot join the trial?

9 criteria

  • Patients who have a different condition than multiple myeloma cannot participate. Multiple myeloma is a type of cancer that affects certain cells in the bone marrow.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are not able to follow the study schedule or take the study medication as required cannot participate.
  • Patients who have other serious health conditions that might interfere with the study cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have had a recent infection or illness that could affect the study cannot participate.
  • Patients who are taking certain medications that might interfere with the study cannot participate.
  • Patients who have a history of allergic reactions to similar medications cannot participate.
  • Patients who have participated in another clinical trial recently cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Talquetamab

    is a humanized bispecific antibody designed to target and bind to two specific proteins, GPRC5D and CD3. It is being studied for its potential to treat patients with relapsed or refractory multiple myeloma, a type of blood cancer. The goal of using talquetamab in this trial is to assess its safety and determine the most effective dose and schedule for future studies. Researchers are also looking at how well it works in treating the cancer.

  • Tocilizumab

    is a medication used in this trial to help prevent or reduce the severity of cytokine release syndrome (CRS), a possible side effect of treatments like talquetamab. CRS can occur when the immune system becomes overly active, and tocilizumab helps manage this by blocking a specific protein involved in the inflammatory response.

What is already known about the treatment

Talquetamab – Talquetamab is administered as an injection, typically given under the skin. It is currently being studied in clinical trials for its potential use in treating multiple myeloma, particularly in patients whose disease has returned or is resistant to other treatments. The medication works by targeting specific proteins on the surface of cancer cells, helping the immune system to recognize and attack these cells. Talquetamab is classified as a bispecific antibody, which means it can bind to two different targets simultaneously, enhancing its ability to engage the immune system against cancer cells.

Investigated diseases

Multiple Myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. These cancerous plasma cells multiply rapidly, leading to an overproduction of abnormal proteins that can cause damage to bones, kidneys, and the immune system. As the disease progresses, it can result in bone pain, fractures, anemia, and increased susceptibility to infections. The accumulation of these abnormal cells can also lead to a decrease in the production of normal blood cells, causing fatigue and weakness. Over time, the disease can cause significant complications, including kidney dysfunction and bone lesions.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2023-504581-29-00Protocol code64407564MMY1001Estimated enrolment422 patientsSponsorJanssen - Cilag International

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.